Optimization of standard AML treatment: APL advances, adverse cytogenetics & post-remission therapy

Optimization of standard AML treatment: APL advances, adverse cytogenetics & post-remission therapy

VJHemOnc

1 year
160 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
With the excitement surrounding novel therapeutics, reliable conventional treatments can often be overlooked. The optimization of standard treatments is a promising area of research, which was discussed in reference to entire spectrum of acute myeloid leukemia (AML) at the 1st International Workshop on Acute Leukemias (iwAL), held in St. Pete Beach, FL. Following this interesting session, the experts got together to discuss the presentation, with Wolfgang Hiddemann, MD, PhD, of Ludwig-Maximilian University of Munich, Munich, Germany, chairing the group in their discussion. He was joined by Laura Cicconi, MD, of the University of Rome Tor Vergata, Rome, Italy, Klaus Metzeler, MD, of LMU-University Hospital Munich, Munich, Germany, and Alan Burnett, MD, FRCP, of Cardiff University, Cardiff, UK. The group cover updates in acute promyelocytic leukemia (APL), addressing the question of where can research go now, covering arsenic trioxide, ATRA and beyond. They next turn to the treatment landscape for AML with adverse cytogenetic features an increasingly large group. With the ever-increasing efficacy of induction treatment, post-remission therapy is a growing area, which the experts then turn their thoughts to. This discussion was recorded at iwAL 2018.
Up Next Autoplay
Caris Life Sciences and Ambry Genetics Partner to Advance Cancer Care
Caris Life Sciences and Ambry Genetics Partner to Advance Cancer Care
Category: News
3 Views
Cancer-News 2 days
Long-Term Results from Phase 3 ALTA-1L Trial
Long-Term Results from Phase 3 ALTA-1L Trial
Category: Non-Small Cell Lung Cancer
26 Views
Cancer-News 3 days
Mount Sinai Receives $1 Million Grant for Prostate Cancer Research
Mount Sinai Receives $1 Million Grant for Prostate Cancer Research
Category: News
2 Views
Cancer-News 3 days
Treatment-Free Survival, With and Without Toxicity
Treatment-Free Survival, With and Without Toxicity
Category: Kidney Cancer
10 Views
kidneycancer 3 days
Phase 2 Study of Lenvatinib Plus Pembrolizumab for Disease Progression After PD-1/PD-L1
Phase 2 Study of Lenvatinib Plus Pembrolizumab for Disease Progression After PD-1/PD-L1
Category: Kidney Cancer
1 Views
kidneycancer 3 days
What's To Come in Modern Imaging Technology
What's To Come in Modern Imaging Technology
Category: Kidney Cancer
4 Views
kidneycancer 4 days
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia
Category: Acute Myelogenous Leukemia
5 Views
Cancer-News 4 days
CytoDyn Reports Early Results from First Patient in its Phase 1b/2 CCR5+ Metastatic Triple-Negative Breast Cancer Trial
CytoDyn Reports Early Results from First Patient in its Phase 1b/2 CCR5+ Metastatic Triple-Negative Breast Cancer Trial
Category: Breast Cancer
6 Views
Cancer-News 4 days
Modern Imaging Technology
Modern Imaging Technology
Category: Kidney Cancer
11 Views
kidneycancer 4 days
ASH Releases New Clinical Practice Guidelines on Immune Thrombocytopenia
ASH Releases New Clinical Practice Guidelines on Immune Thrombocytopenia
Category: News
3 Views
Cancer-News 5 days